Glória Luísa, Bossard Nadine, Bouvier Anne-Marie, Mayer-da-Silva Alexandra, Faivre Jean, Miranda Ana
aDepartment of Epidemiology and South Regional Cancer Registry (ROR-Sul), Portuguese Institute of Oncology, Francisco Gentil, E.P.E, Lisbon, Portugal bDepartment of Biostatistics, University Hospital of Lyon cUniversity of Lyon, Lyon dUniversity of Lyon 1 eCNRS, UMR 5558, Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department Villeurbanne fDigestive Cancer Registry of Burgundy, INSERM U866, CHU Dijon, University of Burgundy, Dijon, France.
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S32-S39. doi: 10.1097/CEJ.0000000000000309.
Gastric cancers are a clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from gastric cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and explore the trends in net survival and in the dynamics of the excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survival for stomach cancer (2000-2004). The 5-year net survival ranged between 26 (Spain) and 32% (Italy). There was a small increase in the age-standardized net survival at 1 year between 1992 and 2004. The increase was also observed in the 5-year net survival, except in France, where the increase was less marked. A slight decrease in the EMR between 1992 and 2004 was limited to the 24 months after diagnosis. In addition, the decrease in the EMR was the same whatever the year of diagnosis. There were minor differences in survival from stomach cancer between European Latin countries. A slight improvement in the 5-year net survival was observed in all countries and the major gain was observed during the 24 months after diagnosis. Development of innovative treatments is needed to improve the prognosis.
胃癌是一项临床挑战。SUDCAN合作研究的目的是比较六个欧洲拉丁国家（比利时、法国、意大利、葡萄牙、西班牙和瑞士）胃癌的净生存率，并探讨诊断后长达5年的净生存率和超额死亡率（EMR）动态变化趋势。数据取自EUROCARE-5数据库。首先，使用Pohar-Perme估计量研究了2000 - 2004年期间的净生存率。对于趋势分析，研究时间段因国家而异。法国、意大利、西班牙和瑞士报告的结果是1992年至2004年的数据，比利时和葡萄牙报告的是2000年至2004年的数据。这些趋势分析采用了灵活的超额率建模策略。各国胃癌年龄标准化净生存率之间差异不大（2000 - 2004年）。5年净生存率在26%（西班牙）至32%（意大利）之间。1992年至2004年，1年时年龄标准化净生存率略有上升。除法国上升不太明显外，5年净生存率也有上升。1992年至2004年，EMR的轻微下降仅限于诊断后的24个月。此外，无论诊断年份如何，EMR的下降情况相同。欧洲拉丁国家之间胃癌生存率存在微小差异。所有国家5年净生存率均略有改善，主要改善发生在诊断后的24个月内。需要开发创新疗法以改善预后。
